Filtered By:
Condition: Ischemic Stroke
Procedure: Percutaneous Coronary Intervention
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 963 results found since Jan 2013.
Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial
CONCLUSIONS: In patients undergoing drug-eluting stent implantation for non-complex lesions, the benefits of 1-month DAPT followed by aspirin monotherapy for a composite of ischaemic and bleeding outcomes were found in patients with stable CAD, but not in those with ACS.CLINICALTRIALS: gov: NCT02513810.PMID:35470799 | DOI:10.4244/EIJ-D-22-00135
Source: EuroIntervention - April 26, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Yong-Joon Lee Jae Young Cho Kyeong Ho Yun Seung-Jun Lee Sung-Jin Hong Chul-Min Ahn Byeong-Keuk Kim Young-Guk Ko Donghoon Choi Myeong-Ki Hong Yangsoo Jang Jung-Sun Kim Source Type: research
Percutaneous Transvalvular Microaxial Flow Pump Support in Cardiology
Circulation. 2022 Apr 19;145(16):1254-1284. doi: 10.1161/CIRCULATIONAHA.121.058229. Epub 2022 Apr 18.ABSTRACTThe Impella device (Impella, Abiomed, Danvers, MA) is a percutaneous transvalvular microaxial flow pump that is currently used for (1) cardiogenic shock, (2) left ventricular unloading (combination of venoarterial extracorporeal membrane oxygenation and Impella concept), (3) high-risk percutaneous coronary interventions, (4) ablation of ventricular tachycardia, and (5) treatment of right ventricular failure. Impella-assisted forward blood flow increased mean arterial pressure and cardiac output, peripheral tissue pe...
Source: Circulation - April 18, 2022 Category: Cardiology Authors: Enzo L üsebrink Antonia Kellnar Kathrin Krieg Leonhard Binzenh öfer Clemens Scherer Sebastian Zimmer Benedikt Schrage Stephanie Fichtner Tobias Petzold Daniel Braun Sven Peterss Stefan Brunner Christian Hagl Dirk Westermann J örg Hausleiter Steffen Mas Source Type: research
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-site, Real-world Investigation
The objective of this study was to validate the ability of ABCD-GENE score to predict risk for atherothrombotic events in a diverse, real-world population of clopidogrel-treated PCI patients who received clinical CYP2C19 genotyping to guide antiplatelet therapy. A total of 2341 adult patients who underwent PCI, were genotyped for CYP2C19, and received treatment with clopidogrel across four institutions were included (mean age 64±12 years, 35% female, 20% Black). The primary outcome was major atherothrombotic events, defined as the composite of all-cause death, myocardial infarction, ischemic stroke, stent thrombosis, or r...
Source: Clinical Pharmacology and Therapeutics - April 16, 2022 Category: Drugs & Pharmacology Authors: Cameron D Thomas Francesco Franchi Ellen C Keeley Joseph S Rossi Marshall Winget R David Anderson Alyssa L Dempsey Yan Gong Megan N Gower Richard A Kerensky Natasha Kulick Jean G Malave Caitrin W McDonough Ian R Mulrenin Petr Starostik Amber L Beitelshees Source Type: research
Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study
CONCLUSIONS: Dual antithrombotic therapy is associated with a substantially lower risk of clinically relevant bleeding without a statistically significant penalty in ischaemic events.PMID:35370126 | DOI:10.4244/EIJ-D-21-00703
Source: EuroIntervention - April 4, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Willem Lambertus Bor Anne Johanna Wilhelmina de Veer Renske H Olie Sem A O F Rikken Dean R P P Chan Pin Yin Jean Paul R Herrman Mathias Vrolix Martijn Meuwissen Tom Vandendriessche Carlos van Mieghem Michael Magro Naoual Bennaghmouch Rick Hermanides Tom A Source Type: research
High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort
CONCLUSION: In this real-world cohort study, higher level of FAR combined with DM was associated with worse 5-year outcomes among patients with CAD undergoing PCI. The level of FAR may help to identify high-risk individuals in this specific population, where more precise risk assessment should be performed.PMID:35313877 | DOI:10.1186/s12933-022-01477-w
Source: Atherosclerosis - March 22, 2022 Category: Cardiology Authors: Peizhi Wang Deshan Yuan Ce Zhang Pei Zhu Sida Jia Ying Song Xiaofang Tang Jingjing Xu Tianyu Li Guyu Zeng Xueyan Zhao Yuejin Yang Bo Xu Runlin Gao Jinqing Yuan Source Type: research
Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial
CONCLUSIONS: Patients free from events at the end of the first year post-PCI and who adhered to their prescribed regimen had a reduced risk of ischaemic events compared to aspirin monotherapy in the second year post-PCI.CLINICALTRIALS: gov: NCT01813435.PMID:35260381 | DOI:10.4244/EIJ-D-21-00870
Source: EuroIntervention - March 9, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Masafumi Ono Hironori Hara Hideyuki Kawashima Chao Gao Rutao Wang Joanna J Wykrzykowska Jan J Piek Scot Garg Christian Hamm Philippe Gabriel Steg Marco Valgimigli Stephan Windecker Pascal Vranckx Yoshinobu Onuma Patrick W Serruys Source Type: research
